281 related articles for article (PubMed ID: 17483155)
1. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
Rosenson RS; Wolff DA; Huskin AL; Helenowski IB; Rademaker AW
Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.
Rosenson RS; Huskin AL; Wolff DA; Helenowski IB; Rademaker AW
Atherosclerosis; 2008 Jun; 198(2):381-8. PubMed ID: 18242616
[TBL] [Abstract][Full Text] [Related]
5. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients.
Rosenson RS
Obesity (Silver Spring); 2009 Mar; 17(3):504-9. PubMed ID: 19023279
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy.
Rosenson RS; Helenowski IB; Tangney CC
Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):439-47. PubMed ID: 20922563
[TBL] [Abstract][Full Text] [Related]
7. Fasting triacylglycerol status, but not polyunsaturated/saturated fatty acid ratio, influences the postprandial response to a series of oral fat tolerance tests.
Dekker MJ; Wright AJ; Mazurak VC; Marangoni AG; Rush JW; Graham TE; Robinson LE
J Nutr Biochem; 2009 Sep; 20(9):694-704. PubMed ID: 18829281
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Hogue JC; Lamarche B; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Mar; 57(3):380-6. PubMed ID: 18249211
[TBL] [Abstract][Full Text] [Related]
9. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
Watts GF; Ji J; Chan DC; Ooi EM; Johnson AG; Rye KA; Barrett PH
Clin Sci (Lond); 2006 Sep; 111(3):193-9. PubMed ID: 16700661
[TBL] [Abstract][Full Text] [Related]
10. [Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].
Zeman M; Zák A; Tvrzická E; Konárková M; Stípek S
Cas Lek Cesk; 2002 Apr; 141(7):211-6. PubMed ID: 12053756
[TBL] [Abstract][Full Text] [Related]
11. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
Roth EM; Bays HE; Forker AD; Maki KC; Carter R; Doyle RT; Stein EA
J Cardiovasc Pharmacol; 2009 Sep; 54(3):196-203. PubMed ID: 19597368
[TBL] [Abstract][Full Text] [Related]
12. High-intensity exercise attenuates postprandial lipaemia and markers of oxidative stress.
Gabriel B; Ratkevicius A; Gray P; Frenneaux MP; Gray SR
Clin Sci (Lond); 2012 Sep; 123(5):313-21. PubMed ID: 22435779
[TBL] [Abstract][Full Text] [Related]
13. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
Bays HE; Maki KC; Doyle RT; Stein E
Postgrad Med; 2009 Sep; 121(5):145-50. PubMed ID: 19820283
[TBL] [Abstract][Full Text] [Related]
14. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
16. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
Levin A; Duncan L; Djurdjev O; Shapiro RJ; Frohlich J; Belanger A; Dumas R; Ross S
Clin Nephrol; 2000 Feb; 53(2):140-6. PubMed ID: 10711416
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate: treatment of hyperlipidemia and beyond.
Rosenson RS
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1319-30. PubMed ID: 19018684
[TBL] [Abstract][Full Text] [Related]
18. Effect of raisin consumption on oxidative stress and inflammation in obesity.
Rankin JW; Andreae MC; Oliver Chen CY; O'Keefe SF
Diabetes Obes Metab; 2008 Nov; 10(11):1086-96. PubMed ID: 18355330
[TBL] [Abstract][Full Text] [Related]
19. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
[TBL] [Abstract][Full Text] [Related]
20. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
